Beam Therapeutics BEAM 深 沪
已收盘 03-27 16:00:00 美东时间
22.19
-1.430
-6.05%
华盛通- 最 高23.79
- 今 开23.46
- 成交量 263.11万股
- 最 低 21.97
- 昨 收 23.62
- 总市值 22.63亿
- 52周最高 36.44
- 市盈率 静 --
- 换手率 2.58%
- 52周最低 13.525
- 委 比 81.93%
- 总股本 1.02亿
- 历史最高 138.522
- 量 比 0.97
- 振 幅 7.71%
- 历史最低 13.00
- 每 手 1
- 风险率 4.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
BUZZ-U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta
BUZZ-U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 25 (Reuters) - Wall Street's main indexes were set to open higher on W
03-25 21:29
Beam Therapeutics Announces Updated Safety And Efficacy Data From Ongoing Phase 1/2 Trial Of BEAM-302 And Selection Of 60 Mg As Optimal Biological Dose To Advance Into Pivotal Development To Support Potential Accelerated Approval
Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-upCorrected M-AAT
03-25 19:09
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Cambridge, MA, March 25, 2026 – Beam Therapeutics announced updated Phase 1/2 trial data for BEAM-302, a base editing therapy for alpha-1 antitrypsin deficiency (AATD). The 60 mg dose achieved mean total AAT levels of 16.1 µM, with all patients consistently above the protective 11 µM threshold. Mutant Z-AAT was reduced by 84%, and adverse events were mild to moderate. Efficacy data support 60 mg as the optimal dose for pivotal development. The co...
03-25 11:00
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit
Beam Therapeutics ( ($BEAM) ) just unveiled an update. On March 2, 2026, Beam T...
03-06 05:45
Cathie Wood's weekly recap: adds defense stock Kratos, CoreWeave, Baidu
Cathie Wood’s ARK Invest ETFs reallocated majorly to AI and defense names, sharply increasing exposure to high-growth AI software and autonomous technology while cutting enterprise software, semicondu...
03-02 20:18
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
What's Going On With Beam Therapeutics Stock?
Beam Therapeutics (NASDAQ: BEAM) shares are rising Tuesday after the company reported quarterly results.
02-25 03:07
Beam Therapeutics Secures $500 Million Credit Facility
Beam Therapeutics ( ($BEAM) ) has shared an update. On February 24, 2026, Beam ...
02-24 20:35
财报速睇 | Beam Therapeutics 2025财年Q4营收1.14亿美元，同比增长279.5%；归母净利润2.44亿美元，扭亏为盈
华盛资讯2月24日讯，Beam Therapeutics公布2025财年Q4业绩，公司Q4营收1.14亿美元，同比增长279.5%，归母净利润2.44亿美元，扭亏为盈。
02-24 20:20
